Yale Medicine School: Following Computational Predictions, Scientists Demonstrate that Cancer Drug Counters Pulmonary Fibrosis
August 25, 2022
August 25, 2022
NEW HAVEN, Connecticut, Aug. 25 (TNSjou) -- Yale School of Medicine issued the following news:
An experimental cancer drug with a favorable safety profile shows promise as a treatment for Idiopathic Pulmonary Fibrosis (IPF), according to a study published on August 23, 2022 in the American Journal of Respiratory and Critical Care Medicine by Yale School of Medicine, Mount Sinai, and National Jewish researchers. The drug, saracatinib, works as well or better than current FDA-approved . . .
An experimental cancer drug with a favorable safety profile shows promise as a treatment for Idiopathic Pulmonary Fibrosis (IPF), according to a study published on August 23, 2022 in the American Journal of Respiratory and Critical Care Medicine by Yale School of Medicine, Mount Sinai, and National Jewish researchers. The drug, saracatinib, works as well or better than current FDA-approved . . .